Calidi Biotherapeutics (CLDI) Accumulated Depreciation & Amortization (2024 - 2025)
Calidi Biotherapeutics' quarterly Accumulated Depreciation & Amortization came in at $1.8 million in Q4 2025, up 32.4% year-on-year from $1.4 million in Q4 2024, and up 4.79% quarter-over-quarter from $1.7 million in Q3 2025.
Calidi Biotherapeutics has reported Accumulated Depreciation & Amortization for 2 years, with the latest figure at $1.8 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 32.4% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.8 million (up 32.4% YoY), and the FY2025 full-year result was $1.8 million, up 32.4% from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 stood at $1.8 million, up from $1.7 million in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $1.8 million in Q4 2025, with the low at $1.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Calidi Biotherapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.79 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Dec 31, 2024 | 1.36 Mn |